Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As OneIUSDF 90 Cash-to-Debt is 4.67 as of Mar. 2026, which is 4% below its 10-year median of 4.85. GuruFocus rates IUSDF with a GF Score™ of 90/100 and a GF Value™ of $17.34. The stock has 4 warning signs investors should review. Among 121 Medical Distribution companies, As One ranks better than 74.38% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. As One's cash to debt ratio for the quarter that ended in Mar. 2026 was 4.67.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, As Onecould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for As One's Cash-to-Debt or its related term are showing as below:
IUSDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.64 Med: 4.85 Max: 6.72
Current: 2.64
During the past 13 years, As One's highest Cash to Debt Ratio was 6.72. The lowest was 2.64. And the median was 4.85.
IUSDF's Cash-to-Debt is ranked better than 74.38% of 121
companies
in the Medical Distribution industry
Industry Median: 0.59
vs IUSDF: 2.64
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
As One Cash-to-Debt Related Terms
As One Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for As One's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Distribution subindustry, As One's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
As One Cash-to-Debt vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, As One's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where As One's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
As One (IUSDF) has a Cash-to-Debt of 4.67 as of Mar. 2026. This is near median its historical median of 4.85. Over the past decade, As One's Cash-to-Debt has ranged from 2.64 to 6.72. According to the industry distribution chart, As One ranks #31 out of 121 companies in the Medical Distribution industry, placing it in the top 25.6%.
Is As One's Cash-to-Debt too high?
As One's current Cash-to-Debt of 4.67 is near median its 10-year median of 4.85. Over the past 10 years, this metric has ranged from a low of 2.64 to a high of 6.72. The Medical Distribution industry median Cash-to-Debt is 0.59. As One's value of 4.67 is 691.5% above this industry median. Based on the distribution chart, As One ranks #31 out of 121 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, As One has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does As One's Cash-to-Debt compare to MCK and COR?
According to the Medical Distribution industry distribution chart, As One ranks #31 out of 121 companies for Cash-to-Debt. This puts As One in the upper half of its industry. The industry median Cash-to-Debt is 0.59. As One's value of 4.67 is 691.5% above this benchmark. Historically, As One's own Cash-to-Debt has ranged from 2.64 to 6.72 over the past decade. While the company's 10-year median is 4.85 vs. the industry median of 0.59, As One has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Distribution company?
The median Cash-to-Debt among Medical Distribution companies is 0.59, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. As One's current Cash-to-Debt of 4.67 is 691.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Cash-to-Debt is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. As One's current Cash-to-Debt is 4.67, which is near median its own 10-year median of 4.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is As One stock overvalued right now?
As One (IUSDF) has a current Cash-to-Debt of 4.67. The stock's GF Value™ is $17.34, compared to a current price of $14.00 — trading 19.3% below its estimated fair value. The current Cash-to-Debt is 4.67, which is near median its 10-year median of 4.85 and 691.5% above the Medical Distribution industry median of 0.59. As One's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For As One (IUSDF), the current Cash-to-Debt is 4.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is As One (IUSDF) Overvalued in 2026?
Based on GuruFocus' analysis, As One stock appears to be undervalued.
The current stock price of $14.00 is trading 19.3% below its estimated GF Value™ of $17.34.
Key valuation signals for IUSDF:
Cash-to-Debt: 4.67 (near median its 10-year median of 4.85)
GF Value™: $17.34 vs. price of $14.00 (19.3% below fair value)
Industry Position: 691.5% above the Medical Distribution median (#31 of 121)
No single metric tells the full story. See the IUSDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
As One Corp is a trading engaged in sale of scientific instruments, industrial instruments, hospital or nursing instruments and approach to specialized fields. The company generates maximum revenue from scientific instrument product line which includes measuring instruments; cultivation, separation, analysis products such as microscopes, glass slides, and tissue culture products; Equipment / storage / conveyance products such as experimental platforms, fume hoods; Vessels or containers which includes storage of samples, reagents; Necessities for experiments including glass or plastic beakers, flask indispensable for experiments, hoses, tubes, joints, plus paper products such as tapes and labels; Equipment for laboratories like timers, packaging machines, tools, office supplies.
90GF Score
Get the complete analysis for IUSDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IUSDF has been successfully added to your 
